BOCA RATON, Fla. (June 30, 2015) — Florida Atlantic University’s Charles E. Schmidt College of Medicine was recently awarded a $2.1 million, two-year contract by Otsuka America Pharmaceutical Inc. to conduct a study to examine the effectiveness of an injectable long-acting antipsychotic medication for schizophrenia and its impact on 30-day hospital readmission rates.
In patients with severe illnesses such as schizophrenia, the risk for relapse and re-hospitalization is substantially increased following hospitalizations. Efforts to promote the use of evidence-based treatments that reduce relapse, improve clinical outcomes and contain health care costs, especially in chronic illnesses, have been a major focus of health quality improvement initiatives in the United States.
